BioAge Raises $90M to Treat Aging and Age-related Diseases
December 03, 2020 08:00 ET
|
BioAge Labs, Inc.
Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging Company announces Chief Medical Officer as it...
BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging, a Root Cause of COVID-19 Morbidity and Mortality in Older Patients
August 25, 2020 08:00 ET
|
BioAge Labs, Inc.
BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175, activating immune-modulating...
BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho’s Phase 1 HIF-PH Inhibitor to Treat Aging
April 29, 2020 22:00 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and age-related diseases, today announced that it has entered into...